Boehringer Ingelheim
Mario Ehlers is an accomplished healthcare professional with extensive experience in clinical development and medical services. Currently serving as Executive Director and Head of Early Clinical Development in Immunology at Boehringer Ingelheim since May 2019, Mario previously held the role of Sr Director, Medical Clinical Services at Eli Lilly and Company. Prior experience includes Deputy Director of the Clinical Trials Group at the Immune Tolerance Network, where involvement focused on advancing immune tolerance therapies, particularly for type 1 diabetes. Mario's background also features roles as Chief Medical Officer at Pacific Biomarkers, Inc. and Restoragen, Inc., alongside significant academic appointments as Professor & Head at the University of Cape Town and Instructor at Harvard Medical School. Mario's educational credentials include a Postdoctoral fellowship in Biochemistry from Harvard Medical School, as well as an MBChB and PhD in Medicine, Surgery, and Biochemistry from the University of Cape Town.
This person is not in any offices
Boehringer Ingelheim
116 followers
At Boehringer Ingelheim they create value through innovation with one clear goal: to improve the lives of patients. They develop breakthrough therapies and innovative healthcare solutions in areas of unmet medical need for both humans and animals. As a family owned company, they focus on long-term performance. They are powered by 50.000 employees globally who nurture a diverse, collaborative and inclusive culture. Learning and development for all employees is key, because your growth is their growth.